Mexico Adult Malignant Glioma Therapeutics Market Analysis

Mexico Adult Malignant Glioma Therapeutics Market Analysis


$ 3999

The Mexico Adult Glioma Therapeutics Market is valued at around $33 Mn in 2022 and is projected to reach $66 Mn by 2030, exhibiting a CAGR of 9.15% during the forecast period. The market is expanding because of advances in current treatment technologies, rising glioma prevalence, particularly among the elderly, and government measures to expand healthcare coverage. Key players in the Mexico Adult Malignant Glioma Therapeutics Market include companies like Roche, Merck & Co., Novartis, Pfizer, AbbVie, Bausch Health, Oncoclínica, SteinCares etc.

ID: IN10MXPH426 CATEGORY: Pharmaceuticals GEOGRAPHY: Mexico AUTHOR: Netal Patel

Buy Now

Mexico Adult Malignant Glioma Therapeutics Market Executive Summary

The Mexico Adult Glioma Therapeutics Market is valued at around $33 Mn in 2022 and is projected to reach $66 Mn by 2030, exhibiting a CAGR of 9.15% during the forecast period.

The most prevalent subtype of primary brain tumours, malignant gliomas, are thought to be among the worst diseases that affect humans because of their aggressiveness, high invasiveness, and neurological damage. Glioblastoma multiforme (GBM), oligodendroglioma, and astrocytoma are the three types of adult-type diffuse gliomas. The most dangerous type of brain tumours are GBMs, or high-grade astrocytomas. Surgery, radiation therapy, and chemotherapy are the current treatments for GBM; nevertheless, the survival benefit is not very great.

The yearly incidence of malignant gliomas in Mexico is about 2.8 per 100,000 people. The incidence rate ratio (IRR) for glioma is around 0.83 (P < 0.0001). The age-adjusted risks of glioma, glioblastoma, diffuse/anaplastic astrocytoma, oligodendroglioma, ependymoma, and pilocytic astrocytoma are all considerably lower in Mexico.

The Mexico Adult Malignant Glioma Therapeutics Market is expanding because of advances in current treatment technologies, rising glioma prevalence, particularly among the elderly, and government measures to expand healthcare coverage.

Key players in the Mexico Adult Malignant Glioma Therapeutics Market include companies like Roche, Merck & Co., Novartis, Pfizer, AbbVie, Bausch Health, Oncoclínica, SteinCares etc.

Mexico Adult Malignant Glioma Therapeutics Market Report 2022 to 2030

Market Dynamics

Market Growth Drivers

Certain factors contribute to the growth of the Adult Malignant Glioma Therapeutics market in Mexico. Using modern tools and procedures to treat glioma improves outcomes. Newer technologies, such as genetic testing and tumour profiling, enable tailored treatment plans based on individual cancer characteristics, increasing efficacy and reducing side effects. Drugs that target specific glioma mutations offer a more precise and effective treatment option than standard chemotherapy. Promising discoveries in immunotherapy have the potential to revolutionize glioma treatment by harnessing the immune system.

The increased prevalence of glioma in Mexico, particularly among the elderly, increases the demand for therapeutic options. Increased life expectancy creates a larger pool of persons susceptible to glioma. Improved diagnostic techniques and knowledge enable early detection and diagnosis of glioma patients.

Government efforts such as Seguro Popular and INSABI seek to provide healthcare coverage to a larger population, perhaps enhancing access to glioma treatment. Private healthcare insurance programs are also increasing, giving patients another way to acquire glioma therapies. Growing investments in infrastructure and healthcare institutions in underprivileged areas can help glioma sufferers get more specialized care.

Market Restraints

Certain barriers like the shortage of skilled neurosurgeons and oncologists with specialized expertise in glioma treatment, result in extended waiting periods and a potential impact on the quality of healthcare. Geographic inequalities in the availability of advanced diagnostic tools and treatment technologies, such as stereotactic radiosurgery, contribute to disparities in care. Additionally, restricted research efforts and delays in clinical trials hinder access to specific treatments.

The delay in diagnosing glioma and the impediment to early intervention can be attributed to the stigma surrounding the disease and a lack of widespread public awareness regarding its symptoms and risk factors. The emotional burden of the illness, coupled with its bleak prognosis, may result in non-compliance with treatment and adversely affect treatment outcomes.

While holding promise, innovative targeted therapies, immunotherapies, and gene therapy can pose a financial challenge for numerous patients and place a burden on healthcare systems. Comprehensive coverage by public and private insurance plans may not be guaranteed, leaving patients with substantial out-of-pocket costs. Consequently, not everyone can afford to access these treatments, resulting in a restricted user base and a limited market.

Healthcare Policies and Regulatory Landscape

The General Health Law oversees Mexico's healthcare regulatory system, and the Federal Commission for Protection against Health Risks (COFEPRIS) enforces it. COFEPRIS is in charge of managing health facilities, regulating health goods, and monitoring advertising activities, whereas the General Health Law covers a wide range of healthcare, sickness prevention, and health product regulation. Furthermore, the country has specific rules covering the use of data, digital health technology, and intellectual property in the healthcare sector. Healthcare providers and other stakeholders operating in Mexico must follow these guidelines to ensure the security, quality, and efficacy of healthcare goods and services delivered there.

Competitive Landscape

Key Players

  • Roche
  • Merck & Co.
  • Novartis
  • Pfizer
  • AbbVie
  • Bausch Health
  • Oncoclínica
  • SteinCares
  • Instituto Nacional de Cancerología (INCan)
  • Brainteech MX

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Mexico Adult Malignant Glioma Therapeutics Market Segmentation

By Disease Type

  • Glioblastoma Multiforme
  • Anaplastic Astrocytoma
  • Anaplastic Oligodendroglioma
  • Anaplastic Oligoastrocytoma
  • Other Types

By Treatment Type

  • Chemotherapy
  • Targeted Drug Therapy
  • Radiation Therapy
  • Surgery
  • Gene Therapy
  • Immunotherapy
  • Vaccines

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Disease Stage

  • Early-Stage Tumour
  • Late-Stage Tumour
  • Palliative Care

By Route of Administration

  • Oral
  • Parenteral
  • Others

By End User

  • Hospitals
  • Speciality Clinics
  • Chemotherapy Centres
  • Radiotherapy Centres
  • Homecare
  • Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 02 February 2024
Updated by: Dhruv Joshi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up